Colorado-based Bolder recently announced the global launch of the CoolSeal vessel sealing platform, which will complement Hologic’s obstetrical/gynecological surgery product line.

Among other Asia deals, Takeda adds to pair of recent gene therapy tie-ups with a CNS-focused cell therapy partnership with Immusoft; earlier it licensed ex-US rights to JCR’s Hunter syndrome drug.

Following the purchase of Mobidiag, Hologic has aggressively launched the Novodiag platform across Europe in a bid to dominate the local molecular diagnostics market.

Six Form 483 observations of GMP deficiencies have been received from the US FDA by Biocon after the agency inspected the Malaysian manufacturing facility for its insulin aspart biosimilar. However, the Indian firm – which is partnered with Viatris on the product, for which an interchangeability designation is also being sought – insisted that US commercialization plans would not be affected.